EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Ayman Abouzayed, Panagiotis Kanellopoulos, Alisa Gorislav, Vladimir Tolmachev iD, Theodosia Maina iD, Berthold A Nock iD, Anna Orlova iD

Biomolecules · 2023

DOI: 10.3390/biom13071134 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomolecules, 2023. Verfasst von Ayman Abouzayed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Receptors, Bombesin. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council (Vetenskaprådet), Swedish Cancer Society (Cancerfonden).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiolabeled gastrin-releasing peptide receptor (GRPR) antagonists have shown great promise for the theranostics of prostate cancer; however, their suboptimal metabolic stability leaves room for improvements. It was recently shown that the replacement of Gly11 with Sar11 in the peptidic [D-Phe6,Leu13-NHEt,des-Met14]BBN(6–14) chain stabilized the [99mTc]Tc-DB15 radiotracer against neprilysin (NEP). We herein present DOTAGA-PEG2-(Sar11)RM26 (AU-RM26-M1), after Gly11 to Sar11-replacement. The impact of this replacement on the metabolic stability and overall biological performance of [111In]In-AU-RM26-M1 was studied using a head-to-head comparison with the unmodified reference [111In]In-DOTAGA-PEG2-RM26. In vitro, the cell uptake of [111In]In-AU-RM26-M1 could be significantly reduced in the presence of a high-excess GRPR-blocker that demonstrated its specificity. The cell uptake of both radiolabeled GRPR antagonists increased with time and was superior for [111In]In-AU-RM26-M1. The dissociation constant reflected strong affinities for GRPR (500 pM for [111In]In-AU-RM26-M1). [111In]In-AU-RM26-M1 showed significantly higher stability in peripheral mice blood at 5 min pi (88 ± 8% intact) than unmodified [111In]In-DOTAGA-PEG2-RM26 (69 ± 2% intact; p < 0.0001). The administration of a NEP inhibitor had no significant impact on the Sar11-compound (91 ± 2% intact; p > 0.05). In vivo, [111In]In-AU-RM26-M1 showed high and GRPR-mediated uptake in the PC-3 tumors (7.0 ± 0.7%IA/g vs. 0.9 ± 0.6%IA/g in blocked mice) and pancreas (2.2 ± 0.6%IA/g vs. 0.3 ± 0.2%IA/g in blocked mice) at 1 h pi, with rapid clearance from healthy tissues. The tumor uptake of [111In]In-AU-RM26-M1 was higher than for [111In]In-DOTAGA-PEG2-RM26 (at 4 h pi, 5.7 ± 1.8%IA/g vs. 3 ± 1%IA/g), concordant with its higher stability. The implanted PC-3 tumors were visualized with high contrast in mice using [111In]In-AU-RM26-M1 SPECT/CT. The Gly11 to Sar11-substitution stabilized [111In]In-DOTAGA-PEG2-(Sar11)RM26 against NEP without negatively affecting other important biological features. These results support the further evaluation of AU-RM26-M1 for prostate cancer theranostics after labeling with clinically relevant radionuclides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsReceptors, BombesinAnimalsHumansMaleMiceCell Line, TumorPrecision Medicine

Stichwörter der Autor:innen

GRPR antagonistPC-3 cellsneprilysinprostate cancertheranostics

Substanzen

Receptors, Bombesin

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, Uppsala University, 751 83 Uppsala, Sweden.
  • Molecular Radiopharmacy, INRaSTES, NCSR "Demokritos", 15310 Athens, Greece.
  • Department of Immunology, Genetics and Pathology, Uppsala University, 751 83 Uppsala, Sweden.
  • Science for Life Laboratory, Uppsala University, 752 37 Uppsala, Sweden.

ORCID-Profile: Vladimir Tolmachev, Theodosia Maina, Berthold A Nock, Anna Orlova

Förderung

  • Swedish Research Council (Vetenskaprådet)
  • Swedish Cancer Society (Cancerfonden)

Zitieren

APA

Abouzayed, A., Kanellopoulos, P., Gorislav, A., Tolmachev, V., Maina, T., Nock, B. A., & Orlova, A. (2023). Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics. Biomolecules. https://doi.org/10.3390/biom13071134

Vancouver

Abouzayed A, Kanellopoulos P, Gorislav A, Tolmachev V, Maina T, Nock BA, et al. Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics. Biomolecules. 2023. doi:10.3390/biom13071134

BibTeX
@article{Abouzayed2023,
  author = {Abouzayed, Ayman and Kanellopoulos, Panagiotis and Gorislav, Alisa and Tolmachev, Vladimir and Maina, Theodosia and Nock, Berthold A and Orlova, Anna},
  title = {Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics},
  journal = {Biomolecules},
  year = {2023},
  doi = {10.3390/biom13071134}
}
Kostenlos starten →